Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioscience Animal Health PCLBKK:BIS -1.44%85 Debt-to-Equity is 0.01 as of Jun. 2026, which is 50% below its 10-year median of 0.02. GuruFocus rates BKK:BIS with a GF Score™ of 85/100 and a GF Value™ of ฿2.62 (Fairly Valued). The stock has 10 warning signs investors should review. Among 1,764 Consumer Packaged Goods companies, Bioscience Animal Health PCL ranks better than 99.94% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Bioscience Animal Health PCL's Debt-to-Equity or its related term are showing as below:
BKK:BIS'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 2.09
Current: 0.01
During the past 9 years, the highest Debt-to-Equity Ratio of Bioscience Animal Health PCL was 2.09. The lowest was 0.01. And the median was 0.02.
BKK:BIS's Debt-to-Equity is ranked better than 99.94% of 1764
companies
in the Consumer Packaged Goods industry
Industry Median: 0.41
vs BKK:BIS: 0.01
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Bioscience Animal Health PCL Debt-to-Equity Related Terms
Bioscience Animal Health PCL Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Bioscience Animal Health PCL's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioscience Animal Health PCL Debt-to-Equity vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Bioscience Animal Health PCL's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Bioscience Animal Health PCL's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioscience Animal Health PCL (BKK:BIS) has a Debt-to-Equity of 0.01 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bioscience Animal Health PCL and its competitors. This is 50% below median its historical median of 0.02. Over the past decade, Bioscience Animal Health PCL's Debt-to-Equity has ranged from 0.01 to 2.09. According to the industry distribution chart, Bioscience Animal Health PCL ranks #1 out of 1764 companies in the Consumer Packaged Goods industry, placing it in the top 0.099999999999994%.
Is Bioscience Animal Health PCL's Debt-to-Equity too high?
Bioscience Animal Health PCL's current Debt-to-Equity of 0.01 is 50% below median its 10-year median of 0.02. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 2.09. The Consumer Packaged Goods industry median Debt-to-Equity is 0.41. Bioscience Animal Health PCL's value of 0.01 is 97.6% below this industry median. Based on the distribution chart, Bioscience Animal Health PCL ranks #1 out of 1764 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Bioscience Animal Health PCL has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bioscience Animal Health PCL's Debt-to-Equity compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Bioscience Animal Health PCL ranks #1 out of 1764 companies for Debt-to-Equity. This places Bioscience Animal Health PCL in the top 0% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.41. Bioscience Animal Health PCL's value of 0.01 is 97.6% below this benchmark. Historically, Bioscience Animal Health PCL's own Debt-to-Equity has ranged from 0.01 to 2.09 over the past decade. While the company's 10-year median is 0.02 vs. the industry median of 0.41, Bioscience Animal Health PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Consumer Packaged Goods company?
The median Debt-to-Equity among Consumer Packaged Goods companies is 0.41, based on 1,764 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioscience Animal Health PCL's current Debt-to-Equity of 0.01 is 97.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Bioscience Animal Health PCL and its competitors. For the Consumer Packaged Goods industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioscience Animal Health PCL's current Debt-to-Equity is 0.01, which is 50% below median its own 10-year median of 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioscience Animal Health PCL stock overvalued right now?
Based on GuruFocus' analysis, Bioscience Animal Health PCL (BKK:BIS) is currently considered Fairly Valued. The stock's GF Value™ is ฿2.62, compared to a current price of ฿2.74 — trading 4.6% above its estimated fair value. The current Debt-to-Equity is 0.01, which is 50% below median its 10-year median of 0.02 and 97.6% below the Consumer Packaged Goods industry median of 0.41. Bioscience Animal Health PCL's overall GF Score™ is 85/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Bioscience Animal Health PCL (BKK:BIS), the current Debt-to-Equity is 0.01 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioscience Animal Health PCL (BKK:BIS) Overvalued in 2026?
Based on GuruFocus' analysis, Bioscience Animal Health PCL stock appears to be overvalued.
The current stock price of ฿2.74 is trading 4.6% above its estimated GF Value™ of ฿2.62.
GuruFocus considers Bioscience Animal Health PCL to be Fairly Valued.
Key valuation signals for BKK:BIS:
Debt-to-Equity: 0.01 (50% below median its 10-year median of 0.02)
GF Value™: ฿2.62 vs. price of ฿2.74 (4.6% above fair value)
Industry Position: 97.6% below the Consumer Packaged Goods median (#1 of 1764)
No single metric tells the full story. See the BKK:BIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioscience Animal Health PCL along with its subsidiaries is engaged in the manufacturing, import and distribution of pharmaceutical supplies, medical devices, equipment and products for livestock and companion animals (pets). Geographically, the company generates revenue from Thailand, and also has presence in other countries.
85GF Score
Get the complete analysis for BKK:BIS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BIS has been successfully added to your 
